

UCSF

UC San Francisco Previously Published Works

Title

Prescription naloxone: a novel approach to heroin overdose prevention

Permalink

<https://escholarship.org/uc/item/2208307d>

Journal

Annals of Emergency Medicine, 49(2)

ISSN

0196-0644

Authors

Sporer, Karl A

Kral, Alex H

Publication Date

2007-02-01

Peer reviewed

Prescription Naloxone: A Novel Approach to Heroin Overdose Prevention

Karl A. Sporer, M.D. FACEP, FACP*

Alex H. Kral, Ph.D.^

*University of California, San Francisco, Department of Medicine, Section of
Emergency Medicine, and the Treatment Research Center

^Urban Health Program, RTI International, and UCSF Department of Family and
Community Medicine

Key Words

Adult

Dose- Response Relationship, Drug

Heroin/administration & dosage

Heroin/antagonists and inhibitors

Heroin/pharmacology

Heroin/poisoning*

Heroin Dependence/complications*

Heroin Dependence/epidemiology*

Humans

Naloxone/pharmacology

Overdose

Overdose/complications

Overdose/epidemiology

Overdose/therapy

Risk Factors

Risk-Taking

Substance Abuse, Intravenous/complications

Corresponding Author:

Karl Sporer, MD

Emergency Services, Room 1E21

San Francisco General Hospital

1001 Potrero Ave.

San Francisco, Ca. 94110

Phone (415)-206-5749

ksporer@sfgghed.ucsf.edu

Funding: None

Financial disclosures: KAS receives compensation for AED medical direction
from American Health and Safety Training, Inc.

Word Count: 2,268

Abstract
Prescription Naloxone:
A Novel Approach to Opiate Overdose Prevention

The mortality and morbidity from heroin overdoses have increased both in the United States and internationally in the last decade. The lipid solubility allows the rapid deposition of heroin and its metabolites into the central nervous system and accounts for both the "rush" experienced by users and the toxicity. Risk factors for fatal and non-fatal heroin overdoses such as recent abstinence, decreased opiate tolerance, and poly-drug use have been identified. Opiate substitution treatment such as methadone or buprenorphine is the only proven method of heroin overdose prevention.

Death from a heroin overdose most commonly occurs at home in the company of other people and most commonly occurs one to three hours after injection. Numerous communities have taken advantage of this opportunity for treatment by implementing overdose prevention education to active heroin users as well as prescribing naloxone for home use. Naloxone is a specific opiate antagonist with no agonist properties and no potential for abuse. It is inexpensive, non-scheduled and readily reverses the respiratory depression and sedation caused by heroin as well as causing transient withdrawal symptoms. Program implementation considerations, legal ramifications, and research needs for prescription naloxone are discussed.

Prescription Naloxone A Novel Approach to Heroin Prevention

Scope of the Heroin Problem

The mortality and morbidity from heroin overdoses increased both in the United States and internationally during the 1990's.¹⁻³ In Australia, the incidence of heroin overdose deaths has increased from 1.3 per million in 1964 to 71.5 in 1997.^{4, 5} Heroin related deaths have been implicated in 9.4% of the total mortality in all persons 15-39 years of age in that country and is the leading cause of death among men aged 25-54 years in Oregon.^{1, 6} In San Francisco, heroin overdose deaths have represented the third leading cause of years of potential life lost.⁷ In 2002, the Drug Abuse Warning Network recorded 93,519 non-fatal heroin overdose related emergency departments visits in the United States representing a 34% increase from 1995.⁸ There has been a recent increase in the abuse of and overdose deaths related to prescription opioids but there have been little research in this area.⁹

The morbidity of non-fatal heroin overdoses has only recently been described. In one study in Australia, 33 percent of patients who had experienced a non-fatal heroin overdose ended up needing treatment in an emergency department. Fourteen percent of these non-fatal heroin overdoses had sufficiently severe injuries, including trauma, burns, assault, pneumonia, or peripheral neuropathy to require hospitalization.¹⁰ Other studies have demonstrated a significant decrease in cognitive function associated with non-fatal heroin overdoses.¹¹

Prescription Naloxone

The unique pharmacology of heroin makes it more likely than other opiates to cause a serious overdose. Heroin and other opiates produce their effects as agonists on the mu, kappa, and delta receptors in the central nervous system. Mu₁ receptors are responsible for most of the analgesic effects, and Mu₂ receptors are responsible for respiratory depression, delayed gastrointestinal motility, miosis, euphoria, and physical dependence.¹² Heroin is more lipid soluble than morphine and other opiates; it therefore crosses the blood-brain barrier within 15 to 20 seconds and achieves relatively high brain levels quickly.¹³ Sixty-eight percent of intravenous heroin is absorbed into the brain compared with less than 5% of intravenous morphine.¹⁴ This lipid solubility allows the rapid deposition of heroin and its metabolites in the central nervous system and accounts for both the "rush" experienced by users and the toxicity.

Risk Factors for Heroin Overdose

Long-term dependent intravenous heroin users who are not in substance abuse treatment are at the greatest risk of a heroin overdose. Heroin overdose victims are disproportionately male, are commonly also abusing benzodiazepines or alcohol.^{4, 12, 15} A recent period of abstinence such as during incarceration or substance abuse treatment, may lead to decreased tolerance and has been shown to be a time of particular risk. Injection heroin users have seven times the risk of death from an overdose during the first two weeks after their release from incarceration.^{12, 16 17} Some authors have demonstrated a preponderance of older opiate users among fatal opiate overdoses in their studies and this may be

Prescription Naloxone

explained by systemic disease processes or by a differing tolerance to the effects of respiratory depression and euphoria.⁵

Two recent intriguing studies of people who had died from an overdose, examined the morphine content of the hair which is a measure of the average use of heroin use over the last few weeks.^{18, 19} Levels of morphine in the hair of fatal overdoses were much closer to those in a control group of abstinent former opiate users than to those of regular users, confirming that recent abstinence and low tolerance are related to death from heroin overdose.

More recent research has described other risk factors, such as an increased use of benzodiazepines or tricyclic antidepressants,²⁰⁻²² and issues with social marginalization such as polysubstance abuse, incarceration, or homelessness.²³⁻²⁸ It has also become clear that patients who have completed a course of naltrexone treatment are at particular risk as well as methadone detoxification programs.²⁹⁻³¹ Some authors have suggested that the preponderance of older opiate users among fatal opiate overdoses may be explained by systemic disease processes or by a differing tolerance to the effects of respiratory depression and euphoria.⁵

Opportunity for Intervention

Death from a heroin overdose most commonly occurs one to three hours after injection.³² Research has shown that most of these deaths occur in the company of other people, and that medical help is not sought or is sought too late.^{7, 33-35} The concern of police involvement has been a consistent barrier for the drug user to access the 911 system.^{23, 36, 37} In cases of non fatal heroin

Prescription Naloxone

overdoses, emergency medical services are only contacted half of the time.^{7, 34, 36, 38} The estimated mortality rate in heroin overdoses managed at home is 10%.¹²

Proven Overdose Prevention

Novel approaches to heroin overdose prevention are needed to stem the epidemic of heroin overdose-related mortality and morbidity.^{4, 32} Methadone maintenance has clearly been shown to decrease deaths from heroin overdoses^{23, 39-45} In a meta-analysis, methadone maintenance reduced heroin users risk of death by 75%, a reduction in mortality almost entirely due to reductions in accidental overdose.⁴¹ French studies performed with buprenorphine maintenance have demonstrated similar benefits.⁴⁶⁻⁴⁸ A recent reduction in the heroin supply in Australia has been demonstrated to reduce fatal and nonfatal overdoses.^{49, 50}

Clearly, increasing options for opiate substitution treatment with methadone and buprenorphine should be the cornerstone of any community's overdose prevention response. Unfortunately, there will likely always be some heroin users not ready for abstinence programs that will need other interventions.

Other strategies have emphasized the reduction of risk factors, improving the response of bystanders, medically supervised injecting rooms, and changing police policy concerning the arrest of overdose victims and witnesses.^{4, 32, 34, 51-54} None of these interventions have been methodically evaluated for their effectiveness in decreasing fatal and non-fatal heroin overdoses.

Prescription Naloxone

Prescription Naloxone

Starting in Europe and progressing to Australia and the United States, communities have begun to provide prescription naloxone for injection drug users (IDU's).^{32, 55-62} In 1995, naloxone was being distributed to heroin users in Germany and England and available over the counter in Turin, Italy.^{63, 64} Surveys of heroin users have demonstrated that most would favor the use of prescription naloxone.^{7, 38, 65} A third of health practitioners in one survey reported being interested in participating in a prescription naloxone program.⁶⁶

In the United States, naloxone was first distributed in 1999 through underground programs first in Chicago and then in San Francisco. There are an unknown number of "underground" programs, organized similarly to underground syringe exchange programs, in which activists and drug users operate informal networks to provide naloxone and education to heroin injectors. In March 2000, the California Medical Association and the San Francisco Department of Public Health recommended the use of prescription naloxone to IDU's as part of a comprehensive overdose management program. In 2001 the San Francisco Department of Public Health sponsored a pilot research study that included opiate education and naloxone prescription.³⁷

In January 2001, New Mexico became the first US state to encourage physicians to prescribe take-home naloxone to heroin injecting patients. In addition, New Mexico's Governor Gary Johnson led the implementation of legislation that releases individuals and medical professionals involved in administering and prescribing naloxone from medical liability. Connecticut and New York followed with laws that provided immunity from civil liability for licensed

Prescription Naloxone

health care practitioners to prescribe, dispense, distribute, and administer opioid antagonists to drug users to prevent overdose deaths.

There are now several prescription naloxone programs operating in US localities, including Chicago, San Francisco, northern New Mexico, Baltimore, New York, and Mendocino County with thousands of injection drug users trained and prescribed naloxone over the last 7 years.⁶⁷⁻⁶⁹ As of February 2006, prescription naloxone programs have reported over nine hundred episodes of peer reversal of a heroin overdose. (See Table 1)

Legalities of a Naloxone Prescription Program

Naloxone, a specific opiate antagonist available by prescription, is inexpensive, non-scheduled, has no abuse potential and is effective at reversing the adverse effects of heroin.^{70, 71} Currently, it is common practice for paramedics to use naloxone in most EMS systems. Prescription naloxone is considered an off label use of the drug.⁶¹ There is considerable precedent for allowing doctors to provide patients or their families with other injectable preparations. Home prescriptions such as rectal valium (diastat) and glucagon are dispensed with the expectation that a family member will administer the medication.

All prescriptions must be written by an appropriate health care provider with a provider client relationship, appropriate record keeping, as well as proper labeling of the medication.⁶¹ All of the current naloxone programs that are sanctioned by their local department of public health in the US (San Francisco, New Mexico, Baltimore, and New York) are dispensing properly labeled kits made out of

Prescription Naloxone

needle proof hardened plastic containers or sunglass cases with the naloxone and syringes.³⁷ Clear procedures for refilling the medication should be developed and local pharmacies should be asked to stock naloxone to honor these prescriptions.

Implementation of a Naloxone Prescription Program

Most naloxone prescription programs include an initial educational component. Several curriculums have been developed and are available online. (www.anypositivechange.org and www.harmreduction.org) Our local experience in San Francisco has led us to believe that shorter (15-20 minute) sessions at syringe exchange program sites are superior vehicles for education than longer classroom venues. Important points for consideration in an educational component are included in Table 2.

The intramuscular route of administration of naloxone is the most easily taught and this route has previously been shown to be effective.^{72, 73} The subcutaneous route has been demonstrated to be comparable to the intravenous route but poses some problems in education.⁷⁴ The intranasal route of naloxone administration was compared to the intramuscular route in one open-label prehospital randomized trial. The intranasal group took slightly longer to achieve the end point of an adequate respiratory rate and had a higher need for rescue intramuscular naloxone but the complication rate (agitation, vomiting, signs of withdrawal) was much lower in this group.⁷³ The intranasal route thus has drawbacks but could be a reasonable compromise in those who may be averse to using needles.

Potential Adverse Outcomes Related to Prescription Naloxone

There are potential adverse outcomes related to prescription naloxone that must be evaluated in any program. There has been concern that heroin users will increase their use because they feel like they have a “parachute” in case they overdose.⁷⁵ The only published prospective evaluation of this concept demonstrated no increase in the frequency of reported heroin injections or rate of personal overdoses.³⁷ It could be argued that distributing naloxone may be construed as implicitly condoning the use of heroin and the safety conferred by naloxone in the home may encourage people to start using heroin. However, there has been no documentation of this phenomenon.

There may be medical and legal implications of naloxone being used by people for whom it was not prescribed. In Seal’s study, only 15% of those treated were the prescribing patients.³⁷ The half life of naloxone is shorter than that of heroin and there is a concern that sedation and respiratory depression has been shown to recur in 15% of suspected heroin overdose patients treated with naloxone.⁷⁶ There may be some reluctance on the part of active heroin users to administer naloxone to acquaintances because of the universally detested withdrawal reaction that accompanies its use. Naloxone treatment of opiate overdose is associated with common complications such as transient moderate to severe withdrawal (17 to 33%) and is associated with a small but consistent rate of complications such as seizures, pulmonary edema and arrhythmias^{72, 76-78} Use of unsterile needles to administer naloxone may transmit HIV, hepatitis C, or other blood borne infections.

Prescription Naloxone

Prescribing naloxone to a patient who has completed an abstinence program may send mixed signals, though it could be presented as a benevolent service to their peers. Finally, there are concerns that the 911 system will not be utilized in the setting of a successful resuscitation. This is disconcerting because prior case series of non-fatal opiate overdoses have demonstrated a 5-12% prevalence of acute hospital admission.^{72, 79} Two studies of prescription naloxone programs have demonstrated that EMS was called in only 10-31% of cases of opiate overdose patient that were successfully resuscitated.^{37, 63} This was lower than the 30-50% previously reported among witnesses of an opiate overdose that did not involve the use of prescription naloxone.

Research Needs

It has been pointed out that current prescription naloxone programs have had little formal evaluation and that published reports have had small sample size, low response rates, significant selection bias, and no formal assessment of complications.⁷⁵ Structured, scientifically sound evaluations of prescription naloxone programs are needed as the number of programs grows. First, we need to evaluate whether these programs are achieving the intended goal of preventing heroin overdose fatalities. Such evaluation efforts need to include assessment of unintended negative consequences of the programs. If shown to be successful without undue negative consequences, we will need a second level of evaluation that involves assessing what are the best practices of such programs. These evaluations could provide important information to guide the

Prescription Naloxone

implementation and design of existing and future prescription naloxone programs.

Conclusion

The international increase in heroin overdoses has led public health authorities and investigators to seek innovative methods of decreasing its morbidity and mortality. Communities should implement proven heroin overdose tactics such as increasing treatment options for methadone or buprenorphine maintenance as their cornerstone strategy. When properly implemented, prescription naloxone can be a legal and safe program. As a complement to opiate substitution treatment, prescription naloxone programs should be considered a standard of care and should be implemented in vulnerable populations. Their effects on mortality, on complication rates, and on patterns of consumption of opiates should be carefully studied.

References

1. Oxman G, Kowalski S, Drapela L, et al. Heroin Overdose Deaths- Multnomah County, Oregon, 1993-1999. *Morbidity and Mortality Weekly Report*. 2000;49(28):633-636.
2. Solet D, Hagan H, Nakagawara J, Plough A, Ball J. Unintentional Opiate Overdose Deaths- King County, Washington, 1990-1999. *Morbidity and Mortality Weekly Report*. 2000;49(28):636-640.
3. Gerostamoulos J, Staikos V, Drummer OH. Heroin-related deaths in Victoria: a review of cases for 1997 and 1998. *Drug Alcohol Depend*. 2001;61(2):123-127.
4. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. *J Urban Health*. Jun 2003;80(2):189-200.
5. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. *Addiction*. 2001;96(8):1113-1125.

Prescription Naloxone

6. Hulse GK, English DR, Milne E, Holman CD. The quantification of mortality resulting from the regular use of illicit opiates. *Addiction*. Feb 1999;94(2):221-229.
7. Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. *J Urban Health*. Jun 2003;80(2):291-301.
8. Emergency Department Trends From DAWN: Final Estimates 1995 - 2002. March 2005;
http://dawninfo.samhsa.gov/old_dawn/pubs_94_02/edpubs/2002final/.
9. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. *Drug Alcohol Depend*. Apr 1 2003;69(3):215-232.
10. Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. *Addiction*. 2002;97(8):963-967.
11. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. *Addiction*. 2000;95(5):687-695.
12. Sporer KA. Acute heroin overdose. *Annals of Internal Medicine*. 1999;130(7):584-590.
13. Way EL, Kemp JW, Young JM, Grassetti DR. The pharmacologic effects of heroin in relationship to its rate of biotransformation. *J Pharmacol Exp Ther*. Jun 1960;129:144-154.
14. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. *Science*. Dec 1 1972;178(64):984-986.
15. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. *Addiction*. Jul 1999;94(7):961-972.
16. Seaman SR, Brettler RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. *BMJ*. 1998;316(7129):426-428.
17. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss AR. Heroin overdose among young injection drug users in San Francisco. *Drug Alcohol Depend*. Dec 12 2005;80(3):297-302.
18. Tagliaro F, De Battisti Z, Smith FP, Marigo M. Death from heroin overdose: findings from hair analysis. *Lancet*. 1998;351(9120):1923-1925.
19. Darke S, Hall W, Kaye S, Ross J, Dufrou J. Hair morphine concentrations of fatal heroin overdose cases and living heroin users. *Addiction*. 2002;97(8):977-984.
20. Darke S, Ross J, Teesson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian Treatment Outcome Study (ATOS). *Addiction*. Aug 2003;98(8):1129-1135.
21. Burns JM, Martyres RF, Clode D, Boldero JM. Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. *Med J Aust*. Oct 4 2004;181(7 Suppl):S25-28.

Prescription Naloxone

22. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. *Med J Aust.* Mar 1 2004;180(5):211-214.
23. Seal K, Kral A, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. *American Journal of Public Health.* 2001;91:1842-1846.
24. O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. *Am J Public Health.* 2001;91(6):984-987.
25. Galea S, Ahern J, Tardiff K, et al. Racial/ethnic disparities in overdose mortality trends in New York City, 1990-1998. *J Urban Health.* Jun 2003;80(2):201-211.
26. Galea S, Ahern J, Vlahov D, et al. Income distribution and risk of fatal drug overdose in New York City neighborhoods. *Drug Alcohol Depend.* May 21 2003;70(2):139-148.
27. Latkin CA, Hua W, Tobin K. Social network correlates of self-reported non-fatal overdose. *Drug Alcohol Depend.* Jan 7 2004;73(1):61-67.
28. Neale J, Robertson M. Recent life problems and non-fatal overdose among heroin users entering treatment. *Addiction.* Feb 2005;100(2):168-175.
29. Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. *Drug Alcohol Depend.* Apr 14 1997;45(1-2):131-134.
30. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). *Addiction.* Apr 2004;99(4):450-460.
31. Oliver P, Horspool M, Keen J. Fatal opiate overdose following regimen changes in naltrexone treatment. *Addiction.* Apr 2005;100(4):560-561.
32. Sporer KA. Strategies for preventing heroin overdose. *Bmj.* Feb 22 2003;326(7386):442-444.
33. Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. *Med J Aust.* Feb 19 1996;164(4):204-207.
34. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. *J Urban Health.* Jun 2003;80(2):261-273.
35. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. *Addiction.* Dec 2002;97(12):1511-1516.
36. Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. *Addiction.* Mar 2005;100(3):397-404.
37. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent

- heroin overdose death: a pilot intervention study. *J Urban Health*. Jun 2005;82(2):303-311.
38. Strang J, Best D, Man L, Noble A, Gossop M. Peer-initiated overdose resuscitation: fellow drug users could be mobilised to implement resuscitation. *Int. J. Drug Policy*. Dec 1 2000;11(6):437-445.
 39. Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users. *Int J Epidemiol*. 1993;22(2):273-277.
 40. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. *Drug Alcohol Depend*. 1981;7(3):249-256.
 41. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. *Subst Use Misuse*. 1996;31(2):177-196.
 42. van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. *Addict Behav*. Jul-Aug 1999;24(4):559-563.
 43. Stewart D, Gossop M, Marsden J. Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). *J Subst Abuse Treat*. Jan 2002;22(1):1-9.
 44. Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CD. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. *Addiction*. Jan 2004;99(1):53-60.
 45. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. *Addiction*. Jul 2005;100(7):981-989.
 46. Ling W, Smith D. Buprenorphine: blending practice and research. *J Subst Abuse Treat*. 2002;23(2):87.
 47. Sporer KA. Buprenorphine: a primer for emergency physicians. *Ann Emerg Med*. May 2004;43(5):580-584.
 48. Gueye PN, Megarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. *Addiction*. Oct 2002;97(10):1295-1304.
 49. Degenhardt LJ, Conroy E, Gilmour S, Hall WD. The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. *Med J Aust*. Jan 3 2005;182(1):20-23.
 50. Degenhardt L, Day C, Dietze P, et al. Effects of a sustained heroin shortage in three Australian States. *Addiction*. Jul 2005;100(7):908-920.
 51. Bammer G. What can a trial contribute to the debate about supervised injecting rooms? *Australian and New Zealand Journal of Public Health*. 2000;24(2):214-215.
 52. Yamey G. UN condemns Australian plans for "safe injecting rooms". *Bmj (Clinical Research Ed.)*. 2000;320(March 11):667.
 53. Dietze P, Jolley D, Cvetkovski S. Patterns and characteristics of ambulance attendance at heroin overdose at a local-area level in

Prescription Naloxone

- Melbourne, Australia: implications for service provision. *J Urban Health*. Jun 2003;80(2):248-260.
54. Tobin KE, Latkin CA. The relationship between depressive symptoms and nonfatal overdose among a sample of drug users in Baltimore, Maryland. *J Urban Health*. Jun 2003;80(2):220-229.
 55. Hall WD. How can we reduce heroin "overdose" deaths? *Med J Aust*. 1996;164(4):197-198.
 56. Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. *Bmj*. 1996;312(7044):1435-1436.
 57. Darke S, Hall W. The distribution of naloxone to heroin users. *Addiction*. 1997;92(9):1195-1199.
 58. Abbasi K. Deaths from heroin overdose are preventable. *BMJ*. 1998;316(7128).
 59. Hall W, Zador D. Challenge of reducing drug-related deaths. *Lancet*. 2000;356(9223):7-8.
 60. Lenton SR, Hargreaves KM. Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose? *Med J Aust*. 2000;173(5):260-263.
 61. Burris S, Norland J, Edlin B. Legal aspects of providing naloxone to heroin users in the United States. *International Journal of Drug Policy*. 2001;12:237-248.
 62. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. *Addiction*. Dec 2005;100(12):1823-1831.
 63. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. *BMJ*. 2001(7291):895-896.
 64. Simini B. Naloxone supplied to Italian heroin addicts. *Lancet*. 1998;352:967.
 65. Sergeev B, Karpets A, Sarang A, Tikhonov M. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. *J Urban Health*. Jun 2003;80(2):212-219.
 66. Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. *J Urban Health*. Jun 2003;80(2):288-290.
 67. Bigg D. Data on take home naloxone are unclear but not condemnatory. *Bmj*. Mar 16 2002;324(7338):678.
 68. Seal KH, Thawley R, Hammond JP, et al. Providing naloxone and training to IDUs can save lives. Paper presented at: American Public Health Association Annual Meeting, 2003; San Francisco, CA.
 69. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City. *Addict Behav*. Aug 31 2005.

Prescription Naloxone

70. Chamberlain J, Klein B. A comprehensive review of naloxone for the emergency physician. *American Journal of Emergency Medicine*. 1994;12:650-660.
71. Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. *Emerg Med J*. Sep 2005;22(9):612-616.
72. Sporer KA, Firestone J, Isaacs SM. Out-of-hospital treatment of opioid overdoses in an urban setting [see comments]. *Academic Emergency Medicine*. 1996;3(7):660-667.
73. Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. *Med J Aust*. Jan 3 2005;182(1):24-27.
74. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose [see comments]. *Academic Emergency Medicine*. 1998;5(4):293-299.
75. Mountain D. Take home naloxone for opiate addicts. Big conclusions are drawn from little evidence. *Bmj*. Oct 20 2001;323(7318):934; author reply 935.
76. Mirakbari SM, Innes GD, Christenson J, Tilley J, Wong H. Do co-intoxicants increase adverse event rates in the first 24 hours in patients resuscitated from acute opioid overdose? *J Toxicol Clin Toxicol*. 2003;41(7):947-953.
77. Osterwalder JJ. Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study [see comments]. *Journal of Toxicology. Clinical Toxicology*. 1996;34(4):409-416.
78. Buajordet I, Naess AC, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. *Eur J Emerg Med*. Feb 2004;11(1):19-23.
79. Daly FFS, Fatovich DM, Bartu A, Quigley A. A prospective study of opioid overdose. *Emergency Medicine*. 2002;14(Supplement):A32.
80. Dietze P, Cantwell K, Burgess S. Bystander resuscitation attempts at heroin overdose: does it improve outcomes? *Drug Alcohol Depend*. 2002;67(2):213-218.

Prescription Naloxone

City	Year of Establishment	Number of trainings/prescriptions	Number of reported overdose reversals
Chicago	1999	4,600	416
New Mexico	2001	1,312	222
San Francisco	2003	650	141
Baltimore	2004	951	131
New York City	2005	938	73

Personal Communication: Dan Bigg, Chicago; Phillip Fiuty, New Mexico; Emalie Hurieux, San Francisco; Monique Rucker, Baltimore; Sharon Stancliff, New York.

Table 2

Implementation of a Prescription Naloxone Program

1. Sites such as syringe exchange programs, drug treatment centers, and jails are logical institutions within which these programs can be placed.
2. Educational Points for Prescription Naloxone Education
 - A. The differentiation between the normal deep lethargy of opiate use (a deep nod) and an opiate overdose. The lack of a response to a sternal rub or other vigorous stimulation, blue lips, absent breathing are all signs of a significant overdose requiring further treatment.
 - B. Rescue breathing should be taught and emphasized. The recovery position should be stressed if rescue breathing is not used. One study has demonstrated a modest decrease in hospitalization rates of non fatal opiate overdose patients when bystander CPR was performed.⁸⁰
 - C. The use of other stimulation such as ice, milk, and amphetamines should be discouraged.
 - D. The importance of contacting emergency medical services and the need for hospital evaluation after an overdose must be stressed because of the complications that can arise.
 - E. The short half-life of naloxone in comparison to heroin and other opiates should be highlighted. The importance of not using more heroin or other opiates within a few hours of revival should be stressed.
 - F. The proper dosing and administration of intramuscular naloxone.
3. The prescription should be provided by a licensed health care provider.

Prescription Naloxone

4. Medical records of the patient encounter and prescription need to be maintained.
5. Any prescribed medication must be properly labeled with the patients name and instructions for use.
6. A system for medication refills should be established.
7. Primary care providers can be instructed in the use of prescription naloxone for patients who are still actively using heroin. Local pharmacies can be involved in honoring these prescriptions.